BJDX · Bluejay Diagnostics, Inc.

Summary

Bluejay Diagnostics, Inc. furnished a response letter dated March 13, 2026, to NorthStrive Fund II LP regarding their March 11, 2026 letter suggesting acquisition of a Phase-1-ready therapeutic program for refractory chronic cough. The Company will evaluate the opportunity while focusing on Symphony platform advancement, SYMON II clinical study, manufacturing scale-up, and FDA submission to preserve cash and unlock shareholder value.

Key takeaways

• Response letter sent to NorthStrive Fund II LP on March 13, 2026, by Neil Dey, President and CEO.
• NorthStrive suggested acquisition of Phase-1-ready therapeutic targeting refractory chronic cough.
• Company prioritizing Symphony platform, SYMON II study completion, manufacturing scale-up, and FDA submission.
• Board and management to review opportunity with advisors, acting in stockholders' best interests.